Mesenchymal Drift Enables Fibrosis Programs
Altos Labs
This turns aging biology into a tractable fibrosis drug map. Mesenchymal drift is useful because it shows up as a measurable shift in cell state across several organs, which gives Altos a way to pick diseases with clear readouts instead of chasing aging as a vague endpoint. In practice, that means tracking the same broad injury program in liver, kidney, lung, and heart tissue, then testing whether reprogramming or small molecules push those cells back toward normal function.
-
The Cell paper tied mesenchymal drift to chronic kidney disease, heart failure, idiopathic pulmonary fibrosis, and metabolic dysfunction associated steatohepatitis. That matters because these are standard disease buckets with existing trial pathways, not speculative longevity categories.
-
Biomarkers are the bridge from mechanism to product. Altos already frames candidates around targets, biomarkers, and preclinical evidence, which means the value of this mechanism is not just biological insight, it is a repeatable way to measure whether an intervention is working before long outcome studies finish.
-
Dorian adds a second way into the same fibrosis markets. Instead of relying only on gene therapy or RNA payloads, Altos can also test small molecules in lung fibrosis and osteoarthritis, which are easier to dose, easier to redose, and more familiar to regulators and pharma partners.
The next step is turning mesenchymal drift from a broad cross organ pattern into the first named clinical program. If Altos can lock down one organ, one biomarker package, and one delivery method, it can reuse that playbook across adjacent fibrotic diseases and move from an aging platform into a multi indication fibrosis company.